key: cord-0888469-qvfuicyl
authors: Kong, Yujie; Cai, Chen; Ling, Li; Zeng, Li; Wu, Meihong; Wu, Yanyun; Zhang, Wei; Liu, Zhong
title: Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma
date: 2020-05-21
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2020.102820
sha: 6ea95d3d4ff4d2ca167afb2b591ac5975145928d
doc_id: 888469
cord_uid: qvfuicyl

BACKGROUND: Because treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored. CASE PRESENTATION AND TREATMENT: A male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion. RESULTS: After convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 × 104 to 1.39 × 103 copies/mL) and became undetectable after the second transfusion. CONCLUSIONS: With the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly.

Since the end of December 2019, an acute pneumonia identified as COVID-19 has becoming a global epidemic. Senior patients are at high risk of COVID-19 and have a high mortality rate due to their decreased immunity [1] , some countries even began to adopt strategies that abandon treatment for elder patients since the limited medical resources. However, antiviral effects of convalescent plasma may provide potential treatment for elder patients. Here we reported a case J o u r n a l P r e -p r o o f of successful treatment of a 100-year-old male COVID-19 patient with convalescent plasma.

A 100-year-old male with a persistent cough, difficulty expectorating, and dyspnea for 2 months was admitted to a tertiary hospital due to COVID-19 in Wuhan, Hubei province in Feb 2020. The patient was a local resident and had no obvious exposure to COVID-19. Initially, he received supportive care at a local geriatric hospital in December 2019. After receiving symptomatic treatment for one week to reduce his cough, the patient continued to suffer from shortness of breath. Two months later, in Feb 2020, the real-time PCR (RT-PCR) test for COVID-19 was performed for the patient at a community health center, and this test yielded a positive result. He was then admitted to a tertiary hospital in Wuhan. The patient had a significant past medical history, including a 30-year record of hypertension, abdominal aortic aneurysm, cerebral infarction, prostate hyperplasia, and complete loss of cognitive function for the preceding 3 years. Upon his hospital admission due to the COVID-19 diagnosis, the patient had stable vital signs, with a body temperature of 36.6 ℃ ( Figure 1A ), pulse of 87 beats/min, respiratory rate of 18 beats/min, blood pressure of 125/63 mmHg, and oxygen saturation of 98% on room air. He had the following laboratory findings: red blood cell and lymphocyte counts were relatively low at 3.47×10 12 /L and 0.75×10 9 /L, respectively, whereas white blood cell, neutrophil, and monocyte counts were within the normal range, at 4.5×10 9 /L , 3.32×10 9 /L, and 0.37×10 9 /L, respectively. C-reactive protein was elevated at 108.43 mg/L. His fibrinogen level Following admission, the patient was given high-flow oxygen, nutritional support, and symptomatic treatment. Due to the patient's advanced age and increased risk for drug-induced toxicity, antiviral medications were not administered at that time. On day 5 of hospitalization, he had a relatively high SARS-CoV-2 viral load (2.55×10 4 copies/mL) by quantitative RT-PCR from a nasopharyngeal swab ( Figure 1B ). Because the patient was not suitable for antiviral treatment and there was no other effective therapy, the clinical team recommended that the patient receive convalescent plasma. Convalescent plasma was collected via plasmapheresis from a donor who had recovered from COVID-19 for more than two weeks and had a SARS-CoV-2 S-RBD-specific IgG titer of >1:640. The patient received convalescent plasma twice from the same donor: 200 ml at 9:45 p.m. on the seventh day of hospitalization and 100 ml at 6:50 p.m. on the eleventh day of hospitalization. After convalescent plasma transfusions, the levels of white blood cells and neutrophils fluctuated but eventually stabilized within the normal range. The absolute lymphocyte counts had a downward trend from the time of admission (from 0.75×10 9 /L to 0.63 ×10 9 /L) but increased after the transfusions of convalescent plasma, reaching 1.08×10 9 /L at the time of discharge ( Figure 1C ). C-reactive protein showed a downward trend after convalescent plasma infusion ( Figure 1D ). IL-6 increased to 66.21 pg/ml after the first infusion of convalescent plasma but subsequently declined ( Figure 1E ). Patient's viral load decreased significantly, by a factor of approximately 18 (from 2.55×10 4 to 1.39×10 3 copies/mL), 24 hours after the first transfusion of convalescent plasma. Following the initial convalescent plasma transfusion, the patient also received antiviral treatment with the J o u r n a l P r e -p r o o f traditional Chinese medicine, but no significant decline in viral load was observed 24 hours after the treatment (from 1.39×10 3 to 1.20×10 3 copies/mL). As a result, a second transfusion of convalescent plasma was given to the patient, and then the viral load became undetectable ( Figure 1B) . The patient had additional viral load testing on days 12 and 13 of hospitalization, with both days producing negative results, and he was discharged on day 13 of hospitalization.

At the time of discharge, the patient had stable vital signs, with significant improvement in his cough and dyspnea. Given the age of the patient and his relatively minor lung changes at presentation, a chest radiograph was not repeated at discharge.

COVID-19 presentations are mainly characterized by fever, fatigue, dry cough, and dyspnea [2] . Sustained reduction of peripheral blood lymphocytes and continuous increases of inflammatory factors can lead to adverse treatment outcomes for patients due to cytokine storm syndrome. Most elderly patients with COVID-19 develop advanced pneumonia and require ICU monitoring as a result of organ failure and declined immunity [3] . Moreover, senior patients have a high mortality rate. The patient in our report is an elderly man with multiple comorbidities. Interestingly, he had a mild presentation with a persistent and prolonged course of COVID-19. He had respiratory symptoms but no obvious fever, although there was some temperature fluctuation ( Figure 1A) , which may be attributable to his advanced age and decreased immunity. Fortunately, this 100-year-old man tolerated the transfusion of convalescent plasma in addition to the standard treatments and achieved good therapeutic outcomes.

The therapeutic effect of convalescent plasma is most likely realized through the antiviral J o u r n a l P r e -p r o o f activity of neutralizing antibodies, but patients may also experience an immune response, which can lead to fluctuations in the level of inflammatory cells and factors [4] [5] . We did observe significant decreases in viral load after convalescent plasma transfusions, suggesting that convalescent plasma therapy may be a viable option for treating COVID-19. This result is consistent with the findings of other reports [6] [7] [8] . We also observed other changes, such as improved cell counts and decreased level of C-reactive protein, as previously reported [9] . The patient tolerated the transfusions well, although there was a transient increase of IL6 level.

Due to a drastic increase in the number of COVID-19 and limited medical resources, several countries have begun to limit or even deny treatments for elderly patients due to their shortened life expectancy and higher mortality rates from COVID-19 [10] . If, however, COVID-19 convalescent plasma is readily available and can be used to treat COVID-19 effectively and safely, its use should be considered in the management of older patients. In addition, untreated elderly patients with COVID-19 and with mild symptoms, such as the patient in our report, may represent a persistent infectious source; therefore, perhaps we should be more vigilant with our treatment decisions for elderly patients if a relatively inexpensive approach such as convalescent plasma is available. 

Zhong Liu and Wei Zhang were responsible for the conceptualization and design of this clinical treatment. Yujie Kong and Chen Cai were responsible for treatment process, data curation, formal analysis and original draft written. Li Zeng, Meihong Wu assisted in clinical treatment and data curation. Yanyun Wu contributed to revision the manuscript.

Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States

Clinical characteristics of 2019 novel coronavirus infection in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Use of convalescent plasma in Ebola virus infection. Transfusion and apheresis science

Use of Plasma Exchange Followed by Convalescent Plasma Therapy in a Critically Ill Patient with Severe Fever and Thrombocytopenia Syndrome-Associated Encephalopathy: Cytokine/Chemokine

Viral Loads, and Antibody Responses

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Convalescent Plasma for Ebola Virus Disease

Convalescent plasma as a potential therapy for COVID-19

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

Facing Covid-19 in Italy -Ethics, Logistics, and Therapeutics on